These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 1389903

  • 1. Effective in vivo induction of lymphokine-activated killer (LAK) cells by pretreatment with a streptococcal preparation, OK-432.
    Shimoda K, Saito T, Kobayashi M, Nomoto K.
    Biotherapy; 1992; 5(1):63-9. PubMed ID: 1389903
    [Abstract] [Full Text] [Related]

  • 2. [A basic study of combination cancer immunotherapy with OK-432 and rIL-2--induction of lymphokine-activated killer (LAK) precursor cells in murine spleen by intravenous administration of OK-432].
    Shimoda K, Saito T, Kobayashi M.
    Nihon Gan Chiryo Gakkai Shi; 1988 Jul 20; 23(7):1566-73. PubMed ID: 3263451
    [No Abstract] [Full Text] [Related]

  • 3. Enhancement of LAK-like activity and cytokine induction in regional lymph nodes and spleen cells of mice after intralymphnodal injection of OK-432, a killed streptococcal preparation.
    Sakakura C, Takahashi T, Hagiwara A, Yamane T, Sawai S, Okano S, Ozaki K, Sasaki S, Tsujimoto H.
    Anticancer Drugs; 1993 Jun 20; 4(3):381-8. PubMed ID: 8358067
    [Abstract] [Full Text] [Related]

  • 4. Lymphokine-activated killer cells and aging in mice: significance for defining the precursor cell.
    Kawakami K, Bloom ET.
    Mech Ageing Dev; 1987 Dec 20; 41(3):229-40. PubMed ID: 2892985
    [Abstract] [Full Text] [Related]

  • 5. [Effect of malignant ascitic fluids and OK-432 on the induction of LAK activity in peripheral blood mononuclear cells of gynecological cancer patients].
    Kanaoka Y, Umesaki N.
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jun 20; 43(6):611-8. PubMed ID: 1856521
    [Abstract] [Full Text] [Related]

  • 6. Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers.
    Nio Y, Zighelboim J, Berek JS, Bonavida B.
    Anticancer Res; 1990 Jun 20; 10(2A):441-6. PubMed ID: 2346317
    [Abstract] [Full Text] [Related]

  • 7. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T.
    Cancer Res; 1988 Mar 01; 48(5):1173-9. PubMed ID: 3257715
    [Abstract] [Full Text] [Related]

  • 8. Synergy of Nocardia rubra cell wall skeleton and interleukin 2 in the in vivo induction of murine lymphokine-activated killer cell activity.
    Kawase I, Komuta K, Shirasaka T, Hara H, Tanio Y, Watanabe M, Saito S, Ikeda T, Masuno T, Kishimoto S.
    Jpn J Cancer Res; 1989 Nov 01; 80(11):1089-97. PubMed ID: 2514171
    [Abstract] [Full Text] [Related]

  • 9. Effects of OK-432 on the proliferation and cytotoxicity of lymphokine-activated killer (LAK) cells.
    Yamamoto K, Tanaka R, Yoshida S, Ono K, Mori H, Taniguchi Y, Oda T, Watanabe T.
    J Immunother; 1999 Jan 01; 22(1):33-40. PubMed ID: 9924697
    [Abstract] [Full Text] [Related]

  • 10. Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.
    Zhai YF, Esselman WJ, Oakley CS, Chang CC, Welsch CW.
    Cancer Immunol Immunother; 1992 Jan 01; 35(4):237-45. PubMed ID: 1511458
    [Abstract] [Full Text] [Related]

  • 11. Induction by OK-432 of lymphokine activated killer precursor cells in hepatocellular carcinoma.
    Aramaki M, Kim YI, Shimoda K, Nakashima K, Okada K, Kobayashi M.
    Hepatogastroenterology; 1994 Aug 01; 41(4):363-6. PubMed ID: 7959572
    [Abstract] [Full Text] [Related]

  • 12. Augmentation of murine lymphokine (rIL-2)-activated killer cell activity by indomethacin.
    Chao TY, Ohnishi H, Chu TM.
    Mol Biother; 1989 Aug 01; 1(6):318-22. PubMed ID: 2610950
    [Abstract] [Full Text] [Related]

  • 13. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.
    Yang JC, Mulé JJ, Rosenberg SA.
    J Immunol; 1986 Jul 15; 137(2):715-22. PubMed ID: 2873187
    [Abstract] [Full Text] [Related]

  • 14. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
    Butler LD, Browne CP, Layman NK, Riedl P, Tang J, Marder P, DeLong D, Manetta J, Bobbitt L, Strnad J.
    Cancer Res; 1988 Nov 01; 48(21):6081-9. PubMed ID: 3048654
    [Abstract] [Full Text] [Related]

  • 15. Phenotypic and functional heterogeneity of thymic and splenic lymphokine activated killer cells relative to ornithine sensitivity.
    Mehrotra P, Bear HD, Susskind BM.
    Cell Immunol; 1991 Feb 01; 132(2):451-65. PubMed ID: 1899052
    [Abstract] [Full Text] [Related]

  • 16. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ, Krosnick JA, Rosenberg SA.
    J Immunol; 1989 Jan 15; 142(2):726-33. PubMed ID: 2783444
    [Abstract] [Full Text] [Related]

  • 17. Augmentation of murine lymphokine-activated killer cell induction by a factor produced by Nocardia rubra cell wall skeleton-stimulated T cells.
    Kawase I, Shirasaka T, Ikeda T, Hara H, Tanio Y, Watanabe M, Saito S, Masuno T, Kishimoto S, Yamamura Y.
    Jpn J Cancer Res; 1989 Nov 15; 80(11):1098-105. PubMed ID: 2481664
    [Abstract] [Full Text] [Related]

  • 18. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y, Zighelboim J, Berek JS, Bonavida B.
    Nat Immun Cell Growth Regul; 1990 Nov 15; 9(4):283-96. PubMed ID: 2215516
    [Abstract] [Full Text] [Related]

  • 19. Acidic polysaccharide from Panax ginseng, ginsan, induces Th1 cell and macrophage cytokines and generates LAK cells in synergy with rIL-2.
    Kim KH, Lee YS, Jung IS, Park SY, Chung HY, Lee IR, Yun YS.
    Planta Med; 1998 Mar 15; 64(2):110-5. PubMed ID: 9525101
    [Abstract] [Full Text] [Related]

  • 20. Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice.
    Gazit Z, Kedar E.
    Cancer Immunol Immunother; 1994 Apr 15; 38(4):243-52. PubMed ID: 8168119
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.